Currie M J, Hanrahan V, Gunningham S P, Morrin H R, Frampton C, Han C, Robinson B A, Fox S B
Department of Pathology, University of Otago, Christchurch School of Medicine and Health Sciences, Christchurch 8001, New Zealand.
J Clin Pathol. 2004 Aug;57(8):829-34. doi: 10.1136/jcp.2003.015644.
Vascular endothelial growth factor D (VEGF-D) induces angiogenesis and lymphangiogenesis. Nodal metastasis is recognised as a powerful prognostic marker in breast carcinoma, but the molecular mechanisms underlying this process are unknown. Although it has been suggested that VEGF-D may regulate nodal metastasis, this is based largely on animal models, its role in human disease being unclear.
To measure the pattern and degree of VEGF-D protein expression in normal and neoplastic human breast tissues.
The pattern and degree of VEGF-D expression was measured in normal tissue and invasive carcinomas, and expression was correlated with clinicopathological parameters, hypoxia markers, and survival. Because other VEGF family members are affected by oestrogen, whether VEGF-D is regulated by oestrogen in breast cancer cell lines was also assessed.
VEGF-D was significantly positively associated with hypoxia inducible factor (HIF-1alpha) (p = 0.03) and the HIF-1alpha regulated gene DEC1 (p = 0.001), but not lymph node status, the number of involved lymph nodes, patient age, tumour size, tumour grade, lymphovascular invasion, oestrogen receptor, progesterone receptor, c-erb-B2, or tumour histology (all p>0.05). There was no significant relation between tumour VEGF-D expression and relapse free (p = 0.78) or overall (p = 0.94) survival. VEGF-D expression was enhanced by oestrogen in MCF-7 and T47D breast cancer cells, and was blocked by hydroxytamoxifen.
These findings support a role for hypoxia and oestrogen induced VEGF-D in human breast cancer and also suggest that tamoxifen and related oestrogen antagonists may exert some of their antitumour effects through the abrogation of VEGF-D induced function.
血管内皮生长因子D(VEGF-D)可诱导血管生成和淋巴管生成。淋巴结转移被认为是乳腺癌中一个强有力的预后标志物,但这一过程的分子机制尚不清楚。尽管有人提出VEGF-D可能调节淋巴结转移,但这主要基于动物模型,其在人类疾病中的作用尚不清楚。
测量人正常乳腺组织和肿瘤性乳腺组织中VEGF-D蛋白表达的模式和程度。
测量正常组织和浸润性癌中VEGF-D的表达模式和程度,并将其表达与临床病理参数、缺氧标志物和生存率相关联。由于其他VEGF家族成员受雌激素影响,因此还评估了乳腺癌细胞系中VEGF-D是否受雌激素调节。
VEGF-D与缺氧诱导因子(HIF-1α)(p = 0.03)和HIF-1α调节基因DEC1(p = 0.001)显著正相关,但与淋巴结状态、受累淋巴结数量、患者年龄、肿瘤大小、肿瘤分级、淋巴管浸润、雌激素受体、孕激素受体、c-erb-B2或肿瘤组织学均无显著相关性(所有p>0.05)。肿瘤VEGF-D表达与无复发生存率(p = 0.78)或总生存率(p = 0.94)之间无显著关系。雌激素可增强MCF-7和T47D乳腺癌细胞中VEGF-D的表达,而羟他莫昔芬可阻断该表达。
这些发现支持缺氧和雌激素诱导的VEGF-D在人类乳腺癌中的作用,也表明他莫昔芬及相关雌激素拮抗剂可能通过消除VEGF-D诱导的功能发挥部分抗肿瘤作用。